←
Editas Medicine737 posts
Editas Medicine avatar

Editas Medicine

@editasmed

Bold Science in Motion: Creating Durable Medicines for Life

◷ Joined April 2014▧ 549 Photos and videos
Editas Medicine avatar
Editas Medicine@editasmed·Nov 16

Last week, Editas participated in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, where we discussed the latest updates on EDIT-401 and our broader pipeline. Listen to the discussion here: bit.ly/47OlBE5. #Guggenheim #invivo

Post attachment
Editas Medicine avatar
Editas Medicine@editasmed·Nov 12

At #AHA2026, Editas shared new preclinical data demonstrating the durability of EDIT-401. The findings presented support EDIT-401’s potential as a transformative therapy for people living with hyperlipidemia. Learn more: bit.ly/4fvsCxB. #invivo

Editas Medicine avatar
Editas Medicine@editasmed·Nov 2

It was a pleasure to participate in this year’s ESGCT Annual Congress. We enjoyed connecting with researchers, innovators, and industry leaders from across the cell and gene therapy community. View our poster presentations here: bit.ly/4jCD0GU. #ESGCT2026 #invivo

Post attachment
Editas Medicine avatar
Editas Medicine@editasmed·Oct 28

On Saturday, Team Editas participated in the @American_Heart Association 2026 Boston Heart Walk, connecting with colleagues and the greater Boston community around heart health. Thank you to AHA for bringing our community together, and to everyone who walked. #BostonHeartWalk

Post attachmentPost attachmentPost attachment
Editas Medicine avatar
Editas Medicine@editasmed·Sep 14

Last week, Editas participated in fireside chats at the Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, sharing updates on EDIT-401 and connecting with the wider healthcare and investment communities. Listen here: bit.ly/4r3c2d4. #invivo

Post attachment
Editas Medicine avatar
Editas Medicine@editasmed·Sep 8

We’re thrilled to welcome Dan Ory, M.D., as Chief Medical Officer at Editas Medicine. Dr. Ory brings decades of experience in cardiovascular disease, genetic medicines, and clinical development as we advance EDIT-401 toward the clinic. Read more: bit.ly/4y1Mwb3 #invivo

Post attachment